G protein γ7 expression as a new clinicopathological marker in patients with intrahepatic cholangiocarcinoma

G protein γ7 expression as a new clinicopathological marker in patients with intrahepatic cholangiocarcinoma
复制标题

DOI:
10.1001/archsurg.137.2.181
复制
发表时间:
2002-02-01
影响因子:
--
通讯作者:
Mori, M
Mori, M
中科院分区:
其他
文献类型:
--
作者:
Utsunomiya, T;Inoue, H;Mori, M

文献摘要

被引文献

相似文献

假设:已在多种癌症中报道了 Ras、Rho 和 Rac 等小 G 蛋白介导的信号改变。最近鉴定并克隆了人类 G 蛋白 gamma7 (G-gamma7) 基因,该基因在各种消化器官癌症中表达下调。因此,G-gamma7 偶联的异三聚体 G 蛋白也可能有助于人类癌症的癌变。地点:大学医院和生物调节医学研究所。患者和方法:检查了 18 例肝内胆管癌 (IHCC) 患者中 G-gamma7 表达的临床病理意义。使用逆转录聚合酶链反应分析确定 G-gamma7 表达的肿瘤与非肿瘤比率。为了可视化 G-gamma7 的定位,进行了免疫组织化学研究。 主要结果测量:人 IHCC 中 G-gamma7 表达的临床病理学意义。 结果:18 名 IHCC 患者中有 17 名 (94%) 的肿瘤组织中 G-gamma7 信使 RNA 的表达低于相应的非肿瘤组织。平均肿瘤与非肿瘤比率为0.54。肿瘤与非肿瘤比率小于 0.5 的 11 名患者的 IHCC 分化程度明显低于肿瘤与非肿瘤比率为 0.5 及以上的 7 名患者(P
Hypothesis: The signal alterations mediated by small G proteins such as Ras, Rho, and Rac have been reported in several cancers. The human G protein gamma7 (G-gamma7) gene, which is down-regulated in various digestive organ cancers, was recently identified and cloned. Thus, the G-gamma7-coupled heterotrimeric G proteins may also contribute to carcinogenesis in human cancers.Setting: University hospital and medical institute of bioregulation.Patients and Methods: The clinicopathological significance of G-gamma7 expression in 18 patients with intrahepatic cholangiocarcinoma (IHCC) was examined. The tumor-nontumor ratio of G-gamma7 expression was determined using reverse transcription polymerase chain reaction analysis. To visualize the localization of G-gamma7, an immunohistochemical study was performed.Main Outcome Measure: Clinicopathological significance of G-gamma7 expression in human IHCC.Results: Expression of G-gamma7 messenger RNA was lower in tumor tissue than in the corresponding nontumor tissue in 17 (94%) of 18 patients with IHCC. The mean tumor-nontumor ratio was 0.54. Eleven patients with tumor-nontumor ratios less than 0.5 showed significantly poorer differentiated IHCC than 7 with tumor-nontumor ratios of 0.5 and greater (P